CR20220275A - Antagonistas heterocíclicos de nmda - Google Patents
Antagonistas heterocíclicos de nmdaInfo
- Publication number
- CR20220275A CR20220275A CR20220275A CR20220275A CR20220275A CR 20220275 A CR20220275 A CR 20220275A CR 20220275 A CR20220275 A CR 20220275A CR 20220275 A CR20220275 A CR 20220275A CR 20220275 A CR20220275 A CR 20220275A
- Authority
- CR
- Costa Rica
- Prior art keywords
- eqn
- prod
- sum
- shapetype
- pixelheight
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019206311A JP2021080177A (ja) | 2019-11-14 | 2019-11-14 | 複素環化合物及びその用途 |
| PCT/IB2020/000962 WO2021094832A1 (en) | 2019-11-14 | 2020-11-12 | Heterocyclic nmda antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20220275A true CR20220275A (es) | 2023-02-17 |
Family
ID=74141594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20220275A CR20220275A (es) | 2019-11-14 | 2020-11-12 | Antagonistas heterocíclicos de nmda |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11834409B2 (enExample) |
| EP (1) | EP4058430A1 (enExample) |
| JP (3) | JP2021080177A (enExample) |
| KR (1) | KR20220102629A (enExample) |
| CN (1) | CN114728900A (enExample) |
| AR (1) | AR120452A1 (enExample) |
| AU (1) | AU2020385250A1 (enExample) |
| BR (1) | BR112022008367A2 (enExample) |
| CA (1) | CA3158352A1 (enExample) |
| CL (1) | CL2022001241A1 (enExample) |
| CO (1) | CO2022008012A2 (enExample) |
| CR (1) | CR20220275A (enExample) |
| DO (1) | DOP2022000099A (enExample) |
| EC (1) | ECSP22037602A (enExample) |
| IL (1) | IL292639A (enExample) |
| JO (1) | JOP20220108A1 (enExample) |
| MX (1) | MX2022005778A (enExample) |
| PE (1) | PE20221767A1 (enExample) |
| PH (1) | PH12022551173A1 (enExample) |
| TW (1) | TWI908745B (enExample) |
| WO (1) | WO2021094832A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL4031552T3 (pl) | 2019-09-16 | 2025-03-17 | Takeda Pharmaceutical Company Limited | Pochodne azolowo-skondensowanych pirydazyn-3(2h)-onów |
| JP2021050161A (ja) | 2019-09-25 | 2021-04-01 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| JP2021080177A (ja) | 2019-11-14 | 2021-05-27 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
| WO2026060343A1 (en) | 2024-09-16 | 2026-03-19 | Neurocrine Biosciences, Inc. | Solid forms comprising a nr2b nam antagonist |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2262453A1 (en) | 1996-08-27 | 1998-03-05 | Praecis Pharmaceuticals Incorporated | Modulators of .beta.-amyloid peptide aggregation comprising d-amino acids |
| JP2000159747A (ja) * | 1998-09-21 | 2000-06-13 | Takeda Chem Ind Ltd | 新規チオ―ル誘導体、その製造法および用途 |
| WO2000017162A1 (en) * | 1998-09-21 | 2000-03-30 | Takeda Chemical Industries, Ltd. | Novel thiol derivatives, process for producing the same and utilization thereof |
| CA2374346C (en) | 1999-06-28 | 2010-06-22 | Jordan J. N. Tang | Inhibitors of memapsin 2 and use thereof |
| EP1235572A2 (en) * | 1999-10-29 | 2002-09-04 | MERCK SHARP & DOHME LTD. | Method to treat pain utilizing benzimidazole nmda/nr2b antagonists |
| JPWO2003035641A1 (ja) * | 2001-10-22 | 2005-02-10 | 塩野義製薬株式会社 | 新規カルバモイルピロリドン誘導体 |
| JP2004002405A (ja) * | 2002-04-26 | 2004-01-08 | Takeda Chem Ind Ltd | 新規チオール誘導体、その製造法および用途 |
| WO2003091242A1 (en) * | 2002-04-26 | 2003-11-06 | Takeda Pharmaceutical Company Limited | Novel thiol derivative, process for producing the same and use thereof |
| TW200732313A (en) * | 2005-12-15 | 2007-09-01 | Astrazeneca Ab | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators |
| TWI403320B (zh) | 2005-12-16 | 2013-08-01 | Infinity Discovery Inc | 用於抑制ｂｃｌ蛋白和結合夥伴間之交互作用的化合物及方法 |
| WO2009004430A1 (en) * | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
| MA39347B2 (fr) | 2014-02-24 | 2020-05-29 | Takeda Pharmaceuticals Co | Protéines de fusion d'uti |
| US10174015B2 (en) * | 2014-10-31 | 2019-01-08 | Xiamen University | Substituted heterocyclic derivative, preparation method and use thereof |
| EP3636281B1 (en) | 2017-05-09 | 2023-11-01 | Zhejiang University | Method for treating depression, and pharmaceutical composition |
| JP6806735B2 (ja) | 2018-05-30 | 2021-01-06 | 矢崎総業株式会社 | 車両用回路体および車両用回路体の製造方法 |
| CN118684633A (zh) | 2018-10-18 | 2024-09-24 | 埃萨制药股份有限公司 | 雄激素受体调节剂及其使用方法 |
| EP3947353A4 (en) | 2019-03-28 | 2023-07-05 | Essa Pharma, Inc. | PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS WITH ANDROGEN RECEPTOR INHIBITORS AND THEIR USES |
| JP2021080177A (ja) | 2019-11-14 | 2021-05-27 | 武田薬品工業株式会社 | 複素環化合物及びその用途 |
-
2019
- 2019-11-14 JP JP2019206311A patent/JP2021080177A/ja active Pending
-
2020
- 2020-11-12 TW TW109139608A patent/TWI908745B/zh active
- 2020-11-12 BR BR112022008367A patent/BR112022008367A2/pt unknown
- 2020-11-12 CA CA3158352A patent/CA3158352A1/en active Pending
- 2020-11-12 PH PH1/2022/551173A patent/PH12022551173A1/en unknown
- 2020-11-12 EP EP20838595.5A patent/EP4058430A1/en active Pending
- 2020-11-12 JP JP2022527713A patent/JP7726879B2/ja active Active
- 2020-11-12 MX MX2022005778A patent/MX2022005778A/es unknown
- 2020-11-12 KR KR1020227019888A patent/KR20220102629A/ko active Pending
- 2020-11-12 PE PE2022000751A patent/PE20221767A1/es unknown
- 2020-11-12 WO PCT/IB2020/000962 patent/WO2021094832A1/en not_active Ceased
- 2020-11-12 CR CR20220275A patent/CR20220275A/es unknown
- 2020-11-12 AR ARP200103139A patent/AR120452A1/es unknown
- 2020-11-12 AU AU2020385250A patent/AU2020385250A1/en active Pending
- 2020-11-12 CN CN202080079710.1A patent/CN114728900A/zh active Pending
-
2022
- 2022-05-01 IL IL292639A patent/IL292639A/en unknown
- 2022-05-10 JO JOP/2022/0108A patent/JOP20220108A1/ar unknown
- 2022-05-12 EC ECSENADI202237602A patent/ECSP22037602A/es unknown
- 2022-05-12 CL CL2022001241A patent/CL2022001241A1/es unknown
- 2022-05-13 DO DO2022000099A patent/DOP2022000099A/es unknown
- 2022-06-06 CO CONC2022/0008012A patent/CO2022008012A2/es unknown
- 2022-12-22 US US18/087,233 patent/US11834409B2/en active Active
- 2022-12-22 US US18/087,302 patent/US11827601B2/en active Active
-
2025
- 2025-08-07 JP JP2025132388A patent/JP2025159062A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7726879B2 (ja) | 2025-08-20 |
| TWI908745B (zh) | 2025-12-21 |
| WO2021094832A1 (en) | 2021-05-20 |
| JP2023502030A (ja) | 2023-01-20 |
| MX2022005778A (es) | 2022-06-09 |
| WO2021094832A8 (en) | 2022-06-02 |
| US20230134307A1 (en) | 2023-05-04 |
| JP2021080177A (ja) | 2021-05-27 |
| JOP20220108A1 (ar) | 2023-01-30 |
| PE20221767A1 (es) | 2022-11-11 |
| KR20220102629A (ko) | 2022-07-20 |
| AU2020385250A1 (en) | 2022-06-30 |
| US11827601B2 (en) | 2023-11-28 |
| US20230002318A1 (en) | 2023-01-05 |
| ECSP22037602A (es) | 2022-06-30 |
| BR112022008367A2 (pt) | 2022-10-18 |
| US20230150934A1 (en) | 2023-05-18 |
| AR120452A1 (es) | 2022-02-16 |
| IL292639A (en) | 2022-07-01 |
| CA3158352A1 (en) | 2021-05-20 |
| US11834409B2 (en) | 2023-12-05 |
| PH12022551173A1 (en) | 2024-02-19 |
| JP2025159062A (ja) | 2025-10-17 |
| CL2022001241A1 (es) | 2023-02-03 |
| TW202132268A (zh) | 2021-09-01 |
| CN114728900A (zh) | 2022-07-08 |
| EP4058430A1 (en) | 2022-09-21 |
| CO2022008012A2 (es) | 2022-06-10 |
| DOP2022000099A (es) | 2022-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20210004B1 (ar) | عوامل تحلّل مستقبلات الإستروجين الانتقائية | |
| DK1054887T3 (da) | Bicykliske pyridin- og pyrimidinderivater som neuropeptid Y-receptorantagonister | |
| AP2002002664A0 (en) | Cyclohexylamine derivative as subtype selective NMDA receptor antagonists. | |
| ATE324371T1 (de) | N-substituierte heterocyclische nichtaryl- nmda/nr2b-antagonisten | |
| DK1135153T3 (da) | Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser | |
| PY0125507A (es) | Agonistas del receptor b3-adrenergico y usos de los mismos | |
| SV2002000440A (es) | Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero ref. pc10869/20160/bb | |
| ATE406360T1 (de) | Antagonisten der opioidrezeptoren | |
| DE69922676D1 (de) | N-aralkylaminotetraline als neuropeptid-y-y5-rezeptorliganden | |
| FI960727A0 (fi) | Neurokiniiniantagonisteina käyttökelpoiset heterosyklit | |
| ES2421948T3 (es) | Compuestos y composiciones para suministrar agentes activos | |
| CR20190433A (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| CY1125335T1 (el) | Ετεροαρυλικες ενωσεις ως αναστολεας κινασης | |
| ES2105525T3 (es) | 2-fenil-3-aroilbenzotiofenos antiestrogenicos como agentes hipoglicemicos. | |
| DOP2022000099A (es) | Antagonistas heterocíclicos de nmda | |
| ATE308522T1 (de) | Opioidrezeptorantagonisten | |
| ECSP088829A (es) | Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1 (cb1) | |
| CO5190711A1 (es) | Antagonistas de los receptores basureros de los macro- fagos | |
| EA200201158A1 (ru) | Бициклические циклогексиламины и их применение в качестве антагонистов nmda-рецепторов | |
| MX2023015074A (es) | Agonistas de sulfonamidas del receptor de orexina y sus usos. | |
| CO2022005861A2 (es) | Terapia de combinación con 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida | |
| AU2001263130A1 (en) | Bicyclic cyclohexylamines and their use as nmda receptor antagonists | |
| SE0002729D0 (sv) | Novel compound form | |
| DE60121048D1 (de) | PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE | |
| NO20035148D0 (no) | Tri- og tetra-aza-acenaftylenderivater som CRF- reseptorantagonister |